Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis
Open Access
- 19 April 2019
- journal article
- review article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 105 (1) , 102-111
Abstract
Immunosuppressive therapy is one therapy option for treatment of patients with lower-risk myelodysplastic syndromes. However, the use of several different immunosuppressive regimens, the lack of high-quality studies, and the absence of validated predictive biomarkers pose important challenges. We conducted a systematic review and meta-analysis according to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines and searched MEDLINE via PubMed, Ovid EMBASE, COCHRANE registry of clinical trials (CENTRAL), and the Web of Science without language restriction from inception through September 2018 as well as relevant conference proceedings and abstracts. for prospective cohort studies or clinical trials investigating immunosuppressive therapy in myelodysplastic syndromes. Fixed and Random-effects models were used to pool response rates. We identified nine prospective cohort studies and 14 clinical trials with a total 570 patients. The overall response rate was 43% (95% confidence interval [CI] 34.2%-52.3%) including a complete remission rate of 12.5% (95% CI 9.3%-16.6%) and red blood cell transfusion independence rate of 30.6% (95% CI 23.2%-39.2%). The most commonly used forms of immunosuppressive therapy were anti-thymocyte globulin alone or in combination with cyclosporin A with a trend towards higher response rates with combination therapy. Progression rate to acute myeloid leukemia was 8.6% per patient year (95% CI 3.3%-13.9%). Overall survival and adverse events were only inconsistently reported. We were unable to validate any biomarkers predictive of a therapeutic response to immunosuppressive therapy. Immunosuppressive therapy for treatment of lower-risk myelodysplastic syndrome patients can be successful to alleviate transfusion burden and associated sequelae.Keywords
This publication has 47 references indexed in Scilit:
- Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic RemissionsJournal of Clinical Oncology, 2010
- Anti‐thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II studyBritish Journal of Haematology, 2010
- Prolonged responses in patients with MDS and CMML treated with azacitidine and etanerceptBritish Journal of Haematology, 2010
- Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatmentHaematologica, 2010
- Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive TherapyJournal of Clinical Oncology, 2008
- Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulinLeukemia, 2007
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Activity of sirolimus in patients with myelodysplastic syndrome - results of a pilot studyBritish Journal of Haematology, 2005
- A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndromeBlood, 2003
- Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin AJournal of Cancer Research and Clinical Oncology, 2003